-Bloomberg
89bio Reports Topline Results From An Expansion Cohort Of The Phase 1b/2a Trial Of Pegozafermin For The Treatment Of NASH
63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and fibrosis improvement